Appeals

Johnson & Johnson unit Ethicon will now be on the hook for damages to 11,000 women implanted with defective pelvic mesh devices, after the High Court declined to hear its appeal of a ruling that found it failed to adequately warn about the devices' risks.

Drug company Ono Pharmaceutical has faced tough questioning by an appeals court in a fight with IP Australia over a decision that secured it a patent extension for its cancer immunotherapy drug Opdivo.

The High Court has found a 15 per cent ‘backpacker tax’ imposed on holders of Australian working holiday visas violates a double taxation agreement between Australia and the UK.

Investors in collapsed stockbroker Halifax Investment Services have failed to overturn decisions in Australia and New Zealand relating to the date of realisation of their investments which have decreased the amount they can recover in the company's liquidation.

A Canberra property developer that misled investors about GST on its apartments does not have to pay compensation to the lead applicant in a class action against it, an appeal court has found.

Three companies operated by convicted accountant Vanda Gould have failed again to block further cross examination of Gould by the Commissioner of Taxation in a number of tax appeals in the Federal Court.

Approving coal mine projects is not the business of courts, the Morrison government has argued in its challenge to a landmark class action judgment that found it had a duty of care to protect Australian children from the effects of climate change.

Former Attorney-General Christian Porter wants to rely on new evidence relating to former Solicitor-General Justin Gleeson SC as he appeals the removal of his high profile silk from a now settled defamation case against the ABC over its coverage of historical rape allegations.

The Murray Darling Basin Authority can’t rely on defences claiming it is a "public or other authority" to limit the liability of a class action brought over alleged negligent water management, an appeals court has found.

Danish drug maker Lundbeck has told the High Court it did not contract away a royalty-free licence to generic drug maker Sandoz to sell blockbuster antidepressant Lexapro, saying such a decision would be commercial “madness”.